Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $12.25 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 80.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,025 shares of the biopharmaceutical company’s stock after buying an additional 16,543 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Alnylam Pharmaceuticals were worth $12,250,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. iA Global Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares in the last quarter. Perpetual Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $2,004,000. Linden Advisors LP bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $6,550,000. WINTON GROUP Ltd lifted its position in shares of Alnylam Pharmaceuticals by 92.5% in the third quarter. WINTON GROUP Ltd now owns 6,800 shares of the biopharmaceutical company’s stock worth $3,101,000 after purchasing an additional 3,267 shares in the last quarter. Finally, Jain Global LLC lifted its position in shares of Alnylam Pharmaceuticals by 366.5% in the third quarter. Jain Global LLC now owns 78,046 shares of the biopharmaceutical company’s stock worth $35,589,000 after purchasing an additional 61,316 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $312.78 on Friday. The company’s fifty day simple moving average is $295.46 and its 200 day simple moving average is $328.42. Alnylam Pharmaceuticals, Inc. has a 12-month low of $273.11 and a 12-month high of $495.55. The firm has a market cap of $41.76 billion, a price-to-earnings ratio of 85.46 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm earned ($0.44) earnings per share. The company’s revenue was up 96.4% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Wall Street analysts now see significant upside for Alnylam, with a recent report highlighting an average price target of $436, which suggests confidence in the stock’s longer-term growth potential.
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $470 price target, even while trimming some near-term earnings estimates, signaling that the firm still expects strong multi-year earnings growth for ALNY.
• Positive Sentiment: Komodo Health expanded its strategic partnership with Alnylam, extending work on Komodo’s Healthcare Map and Marmot analytics AI platform. The collaboration may support Alnylam’s data and AI-driven development efforts and reinforces the company’s commercial and operational execution. Article Title
• Neutral Sentiment: HC Wainwright lowered earnings estimates for Q2, Q3, Q4, FY2026, FY2027, FY2028 and FY2029, but also raised its FY2030 estimate. The revisions suggest some near-term caution, offset by optimism about Alnylam’s longer-term earnings trajectory.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday. Citigroup began coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target for the company. HC Wainwright lowered their target price on shares of Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating on the stock in a report on Monday. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $461.39.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.